Is Indo US Bio-Tech Ltd (INDOUS) a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Indo US Bio-Tech Ltd is a average quality company .

Is Indo US Bio-Tech Ltd (INDOUS) undervalued or overvalued?

The key valuation ratios of Indo US Bio-Tech Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone .

What is Indo US Bio-Tech Ltd (INDOUS) share price return in the past 10 years?

Data is not available for this company

Is Indo US Bio-Tech Ltd (INDOUS) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Indo US Bio-Tech Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

What is the share price of Indo US Bio-Tech Ltd (INDOUS)?

Company share prices are keep on changing according to the market conditions. The current trading price of Indo US Bio-Tech Ltd (INDOUS) on 17-Apr-2026 16:59:59 at 16:59 is 108.00.

What is the P/E ratio of Indo US Bio-Tech?

The latest standalone P/E ratio of Indo US Bio-Tech as of 17-Apr-2026 is 14.60.

What is the P/B ratio of Indo US Bio-Tech Ltd (INDOUS)?

The latest standalone P/B ratio of Indo US Bio-Tech Ltd (INDOUS) as of 17-Apr-2026 is 2.42.

What is the 52-week high and low of Indo US Bio-Tech Ltd (INDOUS)?

The 52-week high of Indo US Bio-Tech Ltd (INDOUS) is Rs. 205.10 and the 52-week low is Rs. 95.00.

Indo US Bio-Tech Ltd (INDOUS) Share Analysis – Quality, Growth & Valuation Zone & DeciZen Rating

Name: Indo US Bio-Tech Ltd (INDOUS)
Brand: Indo US Bio-Tech

Indo US Bio-Tech Ltd (INDOUS) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Indo US Bio-Tech Ltd (INDOUS)

BSE: 541304 NSE: INDOUS

Key Metrics

Market Cap

₹217 Cr.

P/E Ratio

14.60

Price to Book (P/B)

2.42

Price to Sales (P/S)

1.84

EV/EBITDA

13.15

Return on Capital Employed (ROCE)

21.15%

Current Price

₹108

Return on Equity (ROE)

23.03%

Return on Assets (ROA)

17.98%

Operating Profit Margin

18.2%

Net Profit Margin

15.67%

Gross Profit Margin

17%

Book Value per Share

₹44.7

Sales Growth (YoY)

42.56%

Sales Growth (3 Years)

27.54%

Operating Profit Growth (1 Year)

75.37%

Operating Profit Growth (3 Years)

39.81%

Net Profit Growth (1 Year)

97.21%

52-Week Low / High

₹95 / 205

Net Profit Growth (3 Years)

45.91%

Dividend Yield

0.17%

Promoter Holding

68.29%

Pledged shares (%)
of Promoter's holding (%)

0.00%

Check Before You Invest

Q.1 Revenue growth of Indo US Bio-Tech Ltd?

Indo US Bio-Tech Ltd revenue growth is 42.6% for FY-2025 , which is above its 5 year CAGR of 21.2% , indicating faster growth.

Q.1 Promoter shareholding and pledge status of Indo US Bio-Tech Ltd?

Promoters hold 68.29% of the Indo US Bio-Tech Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Revenue growth of Indo US Bio-Tech Ltd vs industry peers?

Indo US Bio-Tech Ltd revenue CAGR is 21.17% , compared to the industry median CAGR of 0% , indicating faster growth and gaining its market share.

Q.1 Which industry/sub-sector does Indo US Bio-Tech Ltd belong to?

Indo US Bio-Tech Ltd belongs to the Agriculture & Allied activities sector, operating specifically within the Agriculture segment.

Q.1 Stock return of Indo US Bio-Tech Ltd over the last decade?

Over the last 5 year(s), the stock has delivered a CAGR of 51.44% based on the current price.

DeciZen - make an informed investing decision on Indo US Bio-Tech

Based on:

Data

Overall Rating ⓘ
Login to view analysis. M-Cap below 500cr. High Risk from low Liquidity

1. Quality

2. Valuation ⓘ

3. Price Trend

Indo US Bio-Tech stock performance

Key Ratios

Is Indo US Bio-Tech Ltd an attractive stock to invest in?

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	7.4%	14.2%	27.8%	20.4%	16.7%	18.3%	15.9%	14.6%	14.4%	21.2%	-
Value Creation Index ⓘ	-0.5	0.0	1.0	0.5	0.2	0.3	0.1	0.0	0.0	0.5	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	19.1	24.5	29.6	35.5	39.8	40.1	50.1	61.7	72.8	104	118
Sales YoY Gr.	-	28.7%	20.9%	19.8%	12%	0.8%	24.8%	23.4%	18%	42.6%	-
Adj EPS ⓘ	0.4	0.4	1.5	1.5	1.8	3.5	2.9	3.6	4.1	8.1	7.4
YoY Gr.	-	11.4%	292.3%	-1.3%	15.9%	100%	-18.3%	26.2%	14.1%	96.8%	-
BVPS (₹) ⓘ	3.2	3.4	4.8	9.5	11.3	14.8	21.2	27.2	31.3	39.2	44.7
Adj Net Profit ⓘ	0.4	0.4	1.6	2.2	2.6	5.1	5.2	7.2	8.3	16.3	15
Cash Flow from Ops. ⓘ	-2.6	0.1	-0.9	-3.2	-0.8	0.2	2.9	0.5	-4.6	1.4	-
Debt/CF from Ops. ⓘ	-1.8	71.5	-7.4	-2	-10.2	51	4.3	22.1	-3.1	10.5	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	20.7%	21.2%	27.5%	42.6%
Adj EPS ⓘ	41.8%	35.9%	41.5%	96.8%
BVPSⓘ	32.2%	28.3%	22.7%	25.2%
Share Price	-	51.4%	-2.8%	-37.7%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	11.7	11.7	37.2	23.3	16.8	26.9	17.3	15.5	14.1	23	17.6
Op. Profit Mgn % ⓘ	2.7	5.1	9.7	10.1	10	13.8	13.9	15.2	14.8	18.2	15.6
Net Profit Mgn % ⓘ	1.9	1.6	5.3	6.2	6.4	12.7	10.5	11.7	11.3	15.7	12.6
Debt to Equity ⓘ	1.4	1.4	1.3	0.5	0.5	0.5	0.3	0.2	0.2	0.2	-
Working Cap Days ⓘ	173	170	161	188	243	322	314	317	331	279	136
Cash Conv. Cycle ⓘ	84	84	102	146	173	214	255	271	295	265	104

Recent Performance Summary

Latest Financials

	Standalone	Consolidated
TTM EPS (₹)	7.4	2.5
TTM Sales (₹ Cr.)	118	50.1
BVPS (₹) ⓘ	44.7	0
Reserves (₹ Cr.) ⓘ	70	29
P/BV ⓘ	2.42	0.00
PE ⓘ	14.60	42.77

From the Market
52 Week Low / High (₹)	95.00 / 205.10
All Time Low / High (₹)	12.85 / 386.00
Market Cap (₹ Cr.)	217
Equity (₹ Cr.)	20.1
Face Value (₹)	10
Industry PE ⓘ	19.3

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Indo US Bio-Tech - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	19	25	30	35	40	40	50	62	73	104
Operating Expenses ⓘ +	19	23	27	32	36	35	43	52	62	85
Manufacturing Costs	1	0	2	7	29	29	48	46	77	79
Material Costs	17	20	23	22	4	0	-9	2	-20	2
Employee Cost	0	0	0	0	0	0	0	1	1	1
Other Costs ⓘ	1	2	2	2	2	5	4	3	3	4
Operating Profit ⓘ	1	1	3	3	4	6	7	9	11	19
Operating Profit Margin (%)	2.7%	5.1%	9.1%	9.6%	10.0%	13.8%	13.8%	15.2%	14.8%	18.2%
Other Income ⓘ +	0	0	0	0	0	0	0	0	0	0
Exceptional Items ⓘ	0	0	0	-0	-0	0	0	0	0	0
Interest ⓘ	0	1	1	0	1	1	1	1	2	1
Depreciation ⓘ	0	0	0	0	0	0	0	1	1	1
Profit Before Tax ⓘ	0	1	2	3	3	4	5	7	9	17
Tax ⓘ	-0	0	1	1	0	-1	0	0	1	0
Profit After Tax	0	0	1	2	3	5	5	7	8	16
PAT Margin (%)	1.9%	1.6%	4.9%	5.9%	6.4%	12.7%	10.5%	11.7%	11.3%	15.7%
Adjusted EPS (₹)	0.4	0.4	1.4	1.4	1.7	3.5	2.9	3.6	4.1	8.1
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	3%

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	3	3	5	14	16	22	39	54	63	79
Share Capital ⓘ	1	1	3	5	6	6	9	10	20	20
Reserves ⓘ	2	2	2	9	10	15	30	44	43	58
Debt +	5	5	6	5	8	11	10	10	13	13
Long Term Debt	0	0	1	1	1	3	3	2	3	3
Short Term Debt	4	4	5	5	7	7	7	8	10	10
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	5	4	5	2	8	9	2	1	4	1
Others Liabilities ⓘ	-0	0	1	2	2	2	4	3	3	4
Total Liabilities ⓘ	13	12	17	24	35	43	55	69	84	97
Fixed Assets
Net Fixed Assets ⓘ +	1	1	2	1	1	2	6	7	7	10
Gross Block	2	2	2	3	1	2	6	7	7	15
Accumulated Depreciation	1	1	0	1	0	0	0	0	0	4
CWIP ⓘ	0	0	0	1	1	2	2	1	4	0
Investments ⓘ	0	0	0	0	0	0	0	0	0	0
Inventories	5	5	6	11	9	12	23	27	52	71
Trade Receivables	6	5	9	9	21	25	21	25	19	15
Cash Equivalents	0	0	0	0	0	0	0	0	1	0
Others Assets ⓘ	1	1	0	1	2	2	3	8	1	1
Total Assets ⓘ	13	12	17	24	35	43	55	69	84	97

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	-3	0	-1	-3	-1	0	3	1	-5	1
PBT ⓘ	0	1	2	3	3	4	5	7	9	17
Adjustment ⓘ	0	0	1	1	1	1	2	2	2	3
Changes in Working Capital ⓘ	-3	-1	-3	-7	-5	-5	-4	-9	-15	-18
Tax Paid ⓘ	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Cash Flow From Investing Activity ⓘ +	-0	-0	0	-3	-1	-2	-5	-7	4	-1
Capex	-0	-0	-0	-1	-0	-2	-4	-2	-3	-1
Net Investments	0	0	0	0	0	-0	0	0	0	0
Others ⓘ	0	0	1	-1	-0	0	-1	-5	7	0
Cash Flow From Financing Activity ⓘ +	3	0	1	6	2	1	2	6	1	-1
Net Proceeds from Shares ⓘ	0	0	0	7	0	0	3	8	0	0
Net Proceeds from Borrowing ⓘ	-0	0	1	-1	-0	3	0	-2	1	0
Interest Paid ⓘ	-0	-0	-1	-0	-1	-1	-1	-1	-2	-1
Dividend Paid ⓘ	0	0	0	0	0	0	-0	0	0	-1
Others ⓘ	3	0	0	-0	3	0	1	1	2	0
Net Cash Flow ⓘ	0	-0	0	0	0	-0	-0	0	1	-1

Finance Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	11.69	11.74	34.36	22.21	16.74	26.87	17.34	15.51	14.08	23.03
ROCE (%)	7.39	14.24	27.84	20.35	16.65	18.3	15.86	14.62	14.42	21.15
Asset Turnover Ratio	1.88	1.95	2.05	1.74	1.36	1.03	1.02	1	0.95	1.15
PAT to CFO Conversion(x)	N/A	N/A	-1	-1.5	-0.33	0	0.6	0.14	-0.63	0.06
Working Capital Days
Receivable Days	66	79	87	93	138	208	165	134	110	60
Inventory Days	91	78	70	87	91	96	128	149	197	215
Payable Days	86	79	64	54	418	0	-223	302	-54	598

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Indo US Bio-Tech Ltd FAQs

The current trading price of Indo US Bio-Tech on 17-Apr-2026 16:59 is ₹108.0.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 16-Apr-2026 the market cap of Indo US Bio-Tech stood at ₹216.6 Cr

The latest P/E ratio of Indo US Bio-Tech as of 16-Apr-2026 is 14.60.

The latest P/B ratio of Indo US Bio-Tech as of 16-Apr-2026 is 2.42.

The 52-week high of Indo US Bio-Tech is ₹205.1 and the 52-week low is ₹95.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Indo US Bio-Tech is ₹118 ( Cr.) .

About Indo US Bio-Tech Ltd

No data to display

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Indo US Bio-Tech Ltd (INDOUS) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Indo US Bio-Tech Share Price